Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Nilay Shah

Clinical Neurophysiology Maywood, NJ Medical Doctor

NPI 1154372621 CMS profile 879770

255 W Spring Valley Ave Ste 102, Maywood, NJ 07607

Open in the dashboard

General payments

$415,410

1,515 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$656

1 holding reported · through program year 2025

Research they led as principal investigator

$8,784 paid to institutions, not to them · program years 2020–2025

Through program year 2025, Nilay Shah of Maywood, NJ is reported in the CMS Open Payments database as having received $415,410 across 1,515 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $8,784 in research payments, paid to institutions rather than to them. They also declared ownership or investment interests valued at $656 across 1 holding.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 97th percentile of Clinical Neurophysiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

8 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $57,000 154
2024 General $107,800 224
2023 General $108,870 288
2022 General $55,017 248
2021 General $25,440 243
2020 General $35,636 194
2019 General $25,646 164
2023 Ownership $656 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Nilay Shah
  • Clinical Neurophysiology median
  • Middle half of Clinical Neurophysiology
  • National median

In program year 2025, general payments to Nilay Shah were reported at $57,000. Among 259 Clinical Neurophysiology profiles paid that year, the median was $435 and the middle half received between $121 and $1,917.

Show as a table
Year Nilay Shah Clinical Neurophysiology median Middle half National median
2019 $25,646 $306 $88–$1,636 $163
2020 $35,636 $299 $85–$1,847 $114
2021 $25,440 $325 $96–$2,308 $132
2022 $55,017 $395 $106–$1,957 $149
2023 $108,870 $388 $120–$1,718 $160
2024 $107,800 $471 $137–$1,931 $164
2025 $57,000 $435 $121–$1,917 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. EMD Serono, Inc. $195,529 341 payments
  2. TG Therapeutics, Inc. $120,857 93 payments
  3. E.R. Squibb & Sons, L.L.C. $32,424 43 payments
  4. SK Life Science, Inc. $27,022 94 payments
  5. ANI Pharmaceuticals, Inc. $7,896 100 payments
  6. Mallinckrodt Enterprises LLC $5,346 16 payments
  7. Kedrion Biopharma, Inc. $4,000 2 payments
  8. Celgene Corporation $3,838 99 payments
  9. Janssen Pharmaceuticals, Inc $2,615 24 payments
  10. Abbott Laboratories $1,433 12 payments
  11. Other $14,451 691 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $302,249 115 payments
  2. Travel and Lodging $43,143 141 payments
  3. Food and Beverage $32,104 1,231 payments
  4. Honoraria $29,550 15 payments
  5. Consulting Fee $7,510 6 payments
  6. Compensation for serving as faculty or as a speaker for a medical education program $770 1 payment
  7. Education $84 6 payments
Products named General payments · program years 2019–2025
  1. Mavenclad Neurology $138,236 100 payments
  2. BRIUMVI $120,857 93 payments
  3. ZEPOSIA $36,216 139 payments
  4. Mavenclad Neurology $28,587 93 payments
  5. XCOPRI $26,110 31 payments
  6. Mavenclad Neurology $18,002 54 payments
  7. PURIFIED CORTROPHIN GEL $6,204 50 payments
  8. REBIF $5,600 2 payments
  9. ACTHAR $5,346 16 payments
  10. KEDRAB $4,000 2 payments
  11. Other $33,814 891 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 40 drugs

Part D claims

3,270

Median for Neurology: 833

Drug cost

$24,813,477

Median for Neurology: $202,670

Branded share of claims

48.3%

Median for Neurology: 25.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Octagam Immun Globg(Igg)/Malt/Iga Ov50 Brand 463 $10,703,062
Gammaplex Immun Glob G(Igg)/Gly/Iga 0-50 Brand 355 $7,819,596
Gammaked Immune Globul G/Gly/Iga Avg 46 Brand 120 $3,560,735
Privigen Immun Glob G(Igg)/Pro/Iga 0-50 Brand 56 $1,011,463
Gamunex-C Immune Globul G/Gly/Iga Avg 46 Brand 54 $973,890
Zeposia Ozanimod Hydrochloride Brand 19 $257,937
Hizentra Immun Glob G(Igg)/Pro/Iga 0-50 Brand 11 $194,568
Kesimpta Pen Ofatumumab Brand 12 $103,146
Xcopri Cenobamate Brand 55 $61,605
Nurtec Odt Rimegepant Sulfate Brand 42 $53,233

The 10 drugs with the highest cost, of 40 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,695 Part D prescribers listed as Neurology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 39 billing codes

Paid by Medicare

$225,704

Medicare's payments for the services billed

Medicare patients

341

Average age 71

Services billed

4,545

209 women, 132 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 49%
Diabetes 43%
Ischemic heart disease 30%
Depression 29%
Chronic kidney disease 26%
Alzheimer's or dementia 26%
Heart failure 18%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 37 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
BRIUMVI
$61,769 — —
Mavenclad
$17,852 — —
ZEPOSIA
$14,652 19 —
XCOPRI
$6,323 55 —
PURIFIED CORTROPHIN GEL
$1,555 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 37 with Patron

Records

1,515 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Clinical Neurophysiology in New Jersey

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record